ArticleOpen life sciences2026
Schisandrin A alleviates allergic rhinitis by restoring Th1/Th2 and Treg/Th17 immune balance.
Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic rhinitis (AR) is a common chronic inflammatory disorder characterized by nasal mucosal inflammation, sneezing, and rhinorrhea. Schisandrin A (Schis-A) has demonstrated significant anti-inflammatory effects in models of allergic asthma. This study aimed to evaluate the therapeutic efficacy of Schis-A in AR and to elucidate its underlying molecular mechanisms. An AR mouse model was established by sensitization and challenge with ovalbumin (OVA), followed by oral administration of Schis-A at doses of 40 and 80 mg/kg/day. Nasal symptoms were monitored and quantified. OVA-specific immunoglobulin E (IgE) levels and T helper (Th)1/Th2- and regulatory T cells (Treg)/Th17-associated cytokines were measured using enzyme-linked immunosorbent assay and quantitative real-time PCR. Treg and Th17 cell populations were analyzed by flow cytometry. The results showed that Schis-A treatment significantly reduced OVA-induced nasal rubbing and sneezing, indicating effective attenuation of allergic responses. Serum OVA-specific IgE levels were markedly reduced in Schis-A-treated AR mice. Moreover, Schis-A restored Th1/Th2 and Treg/Th17 cytokine balance, as indicated by upregulated expression of IFN-γ, IL-2, and Foxp3, alongside downregulation of IL-4, IL-5, IL-13, and IL-17. Flow cytometric analysis confirmed an increase in Treg cells and a reduction in Th17 cell populations. Mechanistically, Schis-A inhibited activation of the PI3K/AKT signaling pathway, suggesting that this pathway may contribute to its immunomodulatory effects. Schis-A alleviates AR by modulating Th1/Th2 and Treg/Th17 immune responses and inhibiting PI3K/AKT pathway activation, offering a promising therapeutic strategy for the treatment of AR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.